Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
August 30, 2023 01:33 ET
|
Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
June 30, 2023 13:32 ET
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
September 19, 2022 02:00 ET
|
Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
September 07, 2022 02:00 ET
|
Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...
Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia
May 22, 2020 16:15 ET
|
Zealand Pharma
Company Announcement – No. 28 / 2020 Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia The dasiglucagon...
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia
March 31, 2020 09:45 ET
|
Zealand Pharma
Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia The...
Zealand Pharma completes equity investment in strategic partner Beta Bionics
January 04, 2019 04:06 ET
|
Zealand Pharma
Press release – No. 1 / 2019 Zealand Pharma completes equity investment in strategic partner Beta Bionics Zealand Pharma invests USD 3.5 million in the final close of strategic partner Beta...